Achieve is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe for more than 20 years. It is estimated that over 20 million people have used cytisinicline to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase 3 clinical trials in Europe and New Zealand. Achieve initiated a Phase 2b Optimization Trial (ORCA-1) evaluating cytisinicline in the United States and data is expected in mid-2019. The Phase 3 cytisinicline development program is expected to begin by the end of 2019. Achieveâs focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. Smoking is currently the leading cause of preventable death and is responsible for nearly six million people losing their lives annually worldwide. Source
No articles found.
IDEXX Laboratories, Inc. is a member of the S&P 500ÂŽ Index and is a leader in pet...
IDEXX Laboratories, Inc. is a member of the S&P...
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...
ChemoCentryx is a biopharmaceutical company foc...
Inovalon is a leading technology company providing cloud-based platforms empowerin...
Inovalon is a leading technology company provid...
Novartis is reimagining medicine to improve and extend peoples lives. As a leadin...
Novartis is reimagining medicine to improve and...
Join the National Investor Network and get the latest information with your interests in mind.